- Home
- UDMY vs PHAR Comparison
UDMY vs PHAR Comparison
Compare UDMY & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UDMY | PHAR |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UDMY | PHAR |
|---|---|---|
| Price | $4.62 | $15.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $9.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 1.8M | 19.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.36 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $789,844,000.00 | N/A |
| Revenue This Year | $4.12 | $27.92 |
| Revenue Next Year | $4.54 | $8.86 |
| P/E Ratio | ★ $159.33 | $3,041.22 |
| Revenue Growth | ★ 0.42 | N/A |
| 52 Week Low | $4.35 | $7.50 |
| 52 Week High | $8.92 | $21.34 |
Technical Indicators
Market Signals| Indicator | UDMY | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 41.15 | 41.57 |
| Support Level | $4.35 | $12.98 |
| Resistance Level | $5.38 | $16.94 |
| Average True Range (ATR) | 0.24 | 0.65 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 8.33 | 12.17 |
Price Performance
Historical ComparisonAbout UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.